
Danish Study: Oral Menopause Hormone Therapy Raises Clot Risk, While Transdermal Shows Better Safety Profile
A large Danish study finds that oral menopausal hormone therapy (MHT) increases the risk of blood clots, stroke, and heart attack, with risks varying by dose and duration. Transdermal MHT shows a significantly better safety profile, with no overall increase in thrombotic events except for a specific combined cyclic regimen. The findings suggest that the route of administration is a critical factor in minimizing cardiovascular risks for women using MHT.




